Novavax is a biotechnology company that specializes in the research and development of vaccines. It was founded in 1987 and is headquartered in Gaithersburg, Maryland, USA. Novavax is dedicated to improving global health by developing innovative vaccines to prevent serious infectious diseases. The company has a diverse portfolio of vaccine candidates, including those for respiratory syncytial virus (RSV), seasonal influenza, and COVID-19. Novavax’s COVID-19 vaccine is based on its proprietary recombinant technology, which enables rapid production of large quantities of vaccine. The company’s COVID-19 vaccine has been authorized for emergency use by regulatory agencies in several countries, including the United Kingdom and the United States.